For those who have an inquiring mind please read the last few announcements and revist the last AGM and make up your own minds. Perhaps even read up on Keytruda, an anti PD-1 drug. FYI when TT was used in combination with the anti PD-1 drug, in mice the efficacy and survival was much improved more than doubled from charts shown, as indicated Giodon in last AGM. Hence the interest shown by MSD
As for the distal effect, from a previous announcement
ABOUT TIGILANOL TIGLATETigilanol tiglate is a novel, small molecule undergoing development as an intratumoural injection treatment for solid tumours. Its effect on tumours is multimodal and involves direct local effects on the injected tumour as well as effects on distal, non-injected tumours. Complete destruction of the injected tumour is mediated via tumour vascular disruption as well as death of tumour cells by oncosis. Following tumour destruction, rapid wound healing has been
This is a recent development and is being followed up on as it is obviously very important Regards
